88 results
Page 4 of 5
8-K
EX-99.1
zot843s01qhfeqt2
15 Jun 20
Regulation FD Disclosure
7:21am
8-K
EX-1.1
g9uz95ep9 re
12 May 20
Entry into a Material Definitive Agreement
5:14pm
424B5
v0z 0byboipl36wk0
12 May 20
Prospectus supplement for primary offering
5:02pm
424B5
3wae1xnhyyg
11 May 20
Prospectus supplement for primary offering
4:12pm
8-K
cd32h2wvr5flqoua
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.2
nswjr 0fd9z
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
424B5
g41vw
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
EX-5.1
il4ka904jk6ct
4 Oct 19
Shelf registration
4:06pm
S-3
EX-1.2
gqm3v jfc5fwcyotn
4 Oct 19
Shelf registration
4:06pm
S-3
worufmyp3t5s
4 Oct 19
Shelf registration
4:06pm
S-3
EX-4.4
ytp d93fsbg
4 Oct 19
Shelf registration
4:06pm
DEF 14A
bng alnvki5k
26 Apr 19
Definitive proxy
12:00am